Venetoclax is highly successful in all CLL and some AML patients, but for other hematological malignancies most notably DLBCL, clinically actionable biomarkers are urgently required to define patient populations most likely to benefit from BCL2 inhibition. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.